The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
The kidney care provider has established over 40 dialysis centres, delivering more than 40,000 dialysis sessions
The precision health platform integrates genetics, biomarkers, diet, and lifestyle data to deliver personalised gut health interventions and therapy support
Conceptualized as an aggregator platform it integrates existing programme systems through an API-based federated architecture
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
The device is designed for early and accurate diagnosis of obstructive airway diseases such as COPD, and Asthma
Designed for high-throughput genomic analysis, the laboratory enables accurate, consistent, and scalable testing, delivering high standards of reporting excellence
Under the new policy, financial assistance has been increased to Rs 50 lakh per patient to improve treatment access
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
